Clinical Trial Update: Autologous T-Cells Expressing a Second Generation CAR for Treatment of T-Cell Malignancies Expressing CD5 Antigen [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating autologous CD5-targeted CAR T cells for T-cell malignancies expressing CD5, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• T-cell Acute Lymphoblastic Leukemia
• T-cell Acute Lymphoblastic Lymphoma
• T-cell Non-hodgkin Lymphoma

Drugs mentioned

• CD5-targeted autologous CAR T cells (CAR-T cell therapy targeting CD5)

Snippet

Sponsor: Baylor College of Medicine | Conditions: T-cell Acute Lymphoblastic Lymphoma, T-non-Hodgkin Lymphoma | Phase 1 | Status: RECRUITING